British Journal of Medical & Surgical Urology
Volume 2, Issue 1 , Pages 11-16 , January 2009

The management of stuttering priapism within a specialist unit—A 25-year experience

Received 13 July 2008 ,Revised 24 September 2008 ,Accepted 2 November 2008.

References 

  1. Pryor J, Akkus E, Alter G, Jordan G, Lebret T, Levine L, et al. Priapism. J Sex Med. 2004;1(1):116–120
  2. Broderick GA, Harkaway R. Pharmacologic erection: time-dependent changes in the corporal environment. Int J Impot Res. 1994;6(1):9–16
  3. Levine LA, Guss SP. Gonadotropin-releasing hormone analogues in the treatment of sickle cell anemia-associated priapism. J Urol. 1993;150(2 Pt 1):475–477
  4. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153(1):152–153
  5. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002;59(1):138
  6. Serjeant GR, De Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2(8467):1274–1276
  7. Gupta S, Salimpour P, Saenz de Tejada I, Daley J, Gholami S, Daller M, et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity. J Urol. 1998;159(5):1529–1536
  8. Gupta S, Moreland RB, Munarriz R, Daley J, Goldstein I, Saenz de Tejada I. Possible role of Na(+)–K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide. Br J Pharmacol. 1995;116(4):2201–2206
  9. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326(2):90–94
  10. Lin G, Xin ZC, Lue TF, Lin CS. Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J Urol. 2003;170(2 Pt 2):S15–S18
  11. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102:1661–1666
  12. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3:1077–1084
  13. Lowe FC, Jarow JP. Placebo-controlled study of oral terbutaline and pseudoephedrine in management of prostaglandin E1-induced prolonged erections. Urology. 1993;42(1):51–53
  14. Okpala I, Westerdale N, Jegede T, Cheung B. Etilefrine for the prevention of priapism in adult sickle cell disease. Br J Haematol. 2002;118(3):918–921
  15. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 2001;85(1):52–53
  16. Desai KM, Gingell JC, Floyd TJ. Preliminary report of a new concept in the pharmacological treatment of erectile impotence using an implantable drug delivery system. Br J Urol. 1987;60(3):267–270
  17. Ralph DJ, Pescatori ES, Brindley GS, Pryor JP. Intracavernosal phenylephrine for recurrent priapism: self-administration by drug delivery implant. J Urol. 2001;165(5):1632
  18. Virag R, Bachir D, Lee K, Galacteros F. Preventive treatment of priapism in sickle cell disease with oral and self-administered intracavernous injection of etilefrine. Urology. 1996;47(5):777–781
  19. Seftel AD, Haas CA, Brown SL, Herbener TE, Sands M, Lipuma J. High flow priapism complicating veno-occlusive priapism: pathophysiology of recurrent idiopathic priapism?. J Urol. 1998;159(4):1300–1301

PII: S1875-9742(08)00114-6

doi: 10.1016/j.bjmsu.2008.11.005

British Journal of Medical & Surgical Urology
Volume 2, Issue 1 , Pages 11-16 , January 2009

Article Tools

* Image Usage & Resolution